Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.50 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.50 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.48 |
| ▸ | F10 | P00742 | 4/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4757094 | 1.00 | NTRK1 (0.50) | NTRK1NTRK3NTRK2F10CSF1R | |
| SCHEMBL4759348 | 0.95 | NTRK1 (0.49) | NTRK1NTRK3NTRK2F10CSF1R | |
| SCHEMBL4759351 | 0.95 | NTRK1 (0.49) | NTRK1NTRK3NTRK2F10CSF1R | |
| SCHEMBL4757933 | 0.94 | NPC1 (0.52) | NTRK1NTRK3NTRK2CSF1RBTK | |
| SCHEMBL4757936 | 0.94 | NPC1 (0.52) | NTRK1NTRK3NTRK2CSF1RBTK | |
| SCHEMBL4703897 | 0.94 | CSF1R (0.54) | NTRK1NTRK3NTRK2F10CSF1R | |
| SCHEMBL4758624 | 0.94 | CSF1R (0.54) | NTRK1NTRK3NTRK2F10CSF1R | |
| SCHEMBL4758964 | 0.93 | NTRK1 (0.54) | NTRK1NTRK3NTRK2F10CSF1R | |
| SCHEMBL4706345 | 0.93 | NTRK1 (0.54) | NTRK1NTRK3NTRK2F10CSF1R | |
| SCHEMBL4758866 | 0.92 | NTRK1 (0.49) | NTRK1NTRK3NTRK2CSF1RFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | NTRK1 413/4885NTRK3 418/4885NTRK2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.